Scarica l'app Stockscreener
30.49
0.93%
-0.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Italy’s Angelini said to explore Catalyst Pharma acquisition - MSN
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Executive Compensation, Stock Awards, and Option Grants 2025 Overview - Minichart
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma - MSN
(CPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived - Pharmaceutical Executive
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - TradingView
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET - Stock Titan
Angelini Pharma Considers Acquisition of Catalyst Pharmaceuticals (CPRX) - GuruFocus
BofA reiterates Catalyst Pharmaceuticals stock rating on M&A report By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Catalyst Pharmaceuticals (CPRX) Shares Surge on Acquisition Inte - GuruFocus
Catalyst Pharmaceuticals jumps on report of potential acquisition interest - Quiver Quantitative
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition - Bloomberg.com
Italy's Angelini said to explore acquisition of Catalyst PharmaBloomberg News - marketscreener.com
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma (CPRX:NASDAQ) - Seeking Alpha
Catalyst Pharmaceuticals stock surges on takeover report By Investing.com - Investing.com Canada
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Italy’s Angelini Said to Explore Acquisition of Catalyst Pharma - Bloomberg.com
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution - Sahm
Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors? - Sahm
How Rare-Disease Drug Momentum At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - TradingView
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high at $26.63 - Investing.com
Is Catalyst (CPRX) stock attracting cautious sentiment | Q4 2025: Better Than ExpectedReal Time Stock Idea Network - Xã Thanh Hà
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
The Bull Case For Catalyst Pharmaceuticals (CPRX) Could Change Following Firdapse Exclusivity Win And Agamree Launch - Sahm
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Strong Buy" from Brokerages - MarketBeat
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
Price-Driven Insight from (CPRX) for Rule-Based Strategy - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Is Up 5.3% After Stronger Revenue And Expanded M&A PipelineWhat's Changed - Sahm
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):